Monitor the U.S. competitive landscape for SCENESSE and the impact of just-in-time inventory changes on future revenue trends. The Phase III vitiligo program and North American expansion strategy are key catalysts to watch, but near-term growth appears capped by EPP market dynamics. Dividend stability and strong cash position provide downside support.
Price Chart
Executive Summary
Clinuvel Pharmaceuticals reported FY2026 annual results with revenue of $94.0M (down 1% YoY) and net profit after tax of $33.9M (down 6% YoY), marking its tenth consecutive annual profit. While cash reserves rose 12% to $252.1M and the company declared a stable $0.05 dividend, the marginal revenue decline and profit drop due to unrealized FX losses and competitive pressure in the U.S. EPP market temper the otherwise solid operational performance.
Key Financial Metrics
Key Facts
- FY2026 revenue $94.0M, down 1% YoY from $95.0M
- Net profit after tax $33.9M, down 6% YoY from $36.2M
- Cash reserves $252.1M, up 12% YoY from $224.1M
- Dividend maintained at $0.05 per share, ninth consecutive annual dividend
- Revenue decline attributed to U.S. competitors offering free EPP drug and shift to just-in-time inventory by specialty centers
- Unrealized FX losses on US$ term deposits caused $4M decline in pre-tax profit
- Ten-year revenue CAGR of 31% and expense CAGR of 18%
- Operating cash inflow $36.9M for FY2026
Financial Impact
Revenue down ~1% to $94.0M; net profit down 6% to $33.9M; cash reserves up 12% to $252.1M
Risk Factors
- Competitive pressure in U.S. EPP market from free drug offerings
- Unrealized FX losses from US$ cash holdings could continue to impact reported profits
- Revenue concentration in SCENESSE with limited near-term pipeline diversification
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3351774 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $5.06 | awaiting T+20 | — | $4.94 (−2.37%) |
Oct 7, 2026 19d ago | 6-K | $5.80 | awaiting T+20 | — | $4.94 (−14.83%) |
Oct 2, 2026 24d ago | 6-K | $6.03 | awaiting T+20 | — | $4.94 (−18.08%) |
Oct 1, 2026 25d ago | 6-K | $5.66 | awaiting T+20 | — | $4.94 (−12.72%) |
Aug 27, 2026 8w ago | 6-K | $6.77 $5.78 | ▼ −14.62% | ▼ −14.12% | $4.94 (−27.03%) |
Aug 27, 2026 8w ago | Press Release | $6.77 $5.78 | ▼ −14.62% | ▼ −14.12% | $4.94 (−27.03%) |
Aug 20, 2026 9w ago | 6-K | $7.80 $5.90 | ▼ −24.36% | ▼ −24.36% | $4.94 (−36.67%) |
Jul 23, 2026 13w ago | 6-K | $6.95 $7.80 | ▲ +12.23% | ▲ +8.92% | $4.94 (−28.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers